# DESCRIPTION

## FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

- disclose government support

## FIELD OF THE DISCLOSURE

- define field

## BACKGROUND OF THE DISCLOSURE

- motivate dry eye treatment

## SUMMARY OF THE DISCLOSURE

- relate to pharmaceutical formulations for ocular surface inflammatory diseases
- provide methods for treating ocular surface inflammatory disease
- describe compositions comprising CCR7 inhibitors
- outline administration of CCR7 inhibitors to ocular or adnexal tissue
- detail CCR7 inhibitors and their effects on Th1 and Th17 responses
- describe suitable forms of the composition
- outline administration frequencies and durations
- describe methods of reducing or preventing migration of antigen-presenting cells
- provide methods of reducing or preventing Th1 and Th17-mediated immunity
- describe methods of preventing ocular surface inflammatory disease
- outline pharmaceutically acceptable carriers and tear substitutes
- define terms and phrases used in the disclosure

## DETAILED DESCRIPTION OF THE INVENTION

- introduce dry eye disease and its prevalence

### Diagnosis of Dry Eye Disease

- describe diagnosis methods for dry eye disease

### CCR7 Antagonist(s)

- introduce CCR7 and its function
- describe types of CCR7 antagonists
- discuss antibody generation against CCR7
- provide examples of small molecule antagonists

### CCL19 and CCL21 Ligands

- introduce CCL19 and CCL21 as CCR7 ligands

### Methods of Use

- describe methods for treating inflammatory conditions of the ocular surface using CCR7 antagonists

### Ophthalmic Formulations

- describe ophthalmic formulations for CCR7 antagonist
- formulate for subconjunctival administration
- formulate for topical administration to the eye
- specify concentration of CCR7 antagonist
- describe carriers and excipients
- adjust pH and tonicity
- describe administration methods

### Example 1

- describe experiment to characterize chemokine receptor expression in DED
- present results of experiment

### Example 2

- describe DED immunopathogenesis
- demonstrate topical CCR7 blockade efficacy
- summarize therapeutic implications

### Other Embodiments

- discuss scope and variations of invention

